NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
National Institutes of Health · Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853)
Publicada 31 ago 2026 · Quedan aproximadamente 29 meses
En pocas palabras
Resumen aún no disponible en español; se muestra en inglés.
The US National Institute of Neurological Disorders and Stroke funds investigator-initiated clinical trials testing treatments for neurological diseases, including early-phase exploratory studies and later-phase confirmatory trials. Both U.S. and foreign organisations may apply with applications due by 9 March 2029, though applications involving foreign subawards must be submitted to a designated international collaboration opportunity instead.
Un resumen generado del texto del donante; la redacción original figura más abajo.
Resumen
Texto original del donante (inglés)
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS and may include studies of small molecules, biologics, devices as well as surgical, behavioral, diet-based, or rehabilitation therapies. Studies addressing neurological diseases and care across the lifespan are highly encouraged. This notice invites both early- and middle-phase exploratory clinical trials as well as later phase confirmatory Phase 3 or comparative effectiveness clinical trials.
Extracto de la página del donante. El texto completo, los anexos y los formularios están en la convocatoria original.
Regiones elegibles
- Todo el mundo
Quién puede presentar una solicitud
- ONG / sociedad civil
- Institución académica o de investigación
- Empresa privada
- Organismo gubernamental
- Organización comunitaria
Elegibilidad y condiciones
Mostrar el texto de elegibilidad de la fuente · Texto original del donante (inglés)
Applicant types: Small businesses; City or township governments; Independent school districts; State governments; Private institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); Special district governments; For profit organizations other than small businesses; Native American tribal governments (Federally recognized); Public housing authorities/Indian housing authorities; County governments
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.